A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Phase 1 Completed 9 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NaSingle-groupOpen-label

Summary

The purpose of this study is to evaluate the potential effect of multiple oral doses of an extended release formulation of paliperidone on the pharmacokinetics (blood levels) of valproic acid (VPA) in patients with schizophrenia, bipolar I disorder, or schizoaffective disorder.

Timeline

Start: 2009-02
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Divalproex Sodium	Small molecule	—	Oral
Subject	Paliperidone	Unknown	12 mg	Oral

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Summary

Timeline

Drugs

Indications